Basic Information
| LncRNA/CircRNA Name | CRAL |
| Synonyms | cisplatin resistance-associated lncRNA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | Microarray, qRT-PCR, Western blot, Luciferase reporter assay |
| Sample | two cisplatin-sensitive GC cells BGC823 and SGC7901 and their parent cisplatin-resistant GC cell lines BGC823/DDP and SGC7901/DDP. |
| Expression Pattern | down-regulated |
| Function Description | cisplatin resistance-associated lncRNA (CRAL), that was downregulated in cisplatin-resistant GC cells, impaired cisplatin-induced DNA damage and cell apoptosis and thus contributed to cisplatin resistance in GC cells. Furthermore, the results indicated that CRAL mainly resided in the cytoplasm and could sponge endogenous miR-505 to upregulate cylindromatosis (CYLD) expression, which further suppressed AKT activation and led to an increase in the sensitivity of gastric cancer cells to cisplatin in vitro and in preclinical models. |
| Pubmed ID | 31885317 |
| Year | 2020 |
| Title | The Long Noncoding RNA CRAL Reverses Cisplatin Resistance via the miR-505/CYLD/AKT Axis in Human Gastric Cancer Cells |
External Links
| Links for CRAL | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |